SHINE Medical Technologies, a Monona, Wis.-based medical isotope manufacturer, announced this week that the U.S. Nuclear Regulatory Commission (NRC) has officially authorized the construction permit for SHINE’s medical isotope construction facility to be issued.
The NRC first recommended approval of the permit back in October 2015. The facility will be used for the production of molybdenum-99 (Mo-99) without highly enriched uranium.
Greg Piefer, SHINE CEO, said in a prepared statement that this was a historic moment for the company.
“This is the first time in over fifty years a medical isotope plant of this kind has been granted a construction permit,” Piefer said. “We’ve developed a greener, safer, and cheaper way to produce these life-saving isotopes on a global scale. Once operational we expect the Janesville facility will improve the lives of over 1 billion people over its lifetime. It’s a very exciting time at SHINE.”
“SHINE diligently followed the clear regulatory path provided by the NRC, resulting in the regulatory clearance to build our facility in Janesville,” Jim Costedio, SHINE vice president of regulatory affairs and quality, said in the same statement.
A celebration is being planned for next month in Janesville, Wis., where the facility will be built.
Michael has more than 16 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.